Navigation Links
Pervasis Therapeutics Announces Late-Breaking Oral Presentation at American Association for Cancer Research Annual Meeting
Date:3/22/2011

CAMBRIDGE, Mass., March 22, 2011 /PRNewswire/ -- Pervasis Therapeutics, Inc. today announced that researchers will present pre-clinical data related to PVS-30200, the company's investigational cell therapy for the treatment of solid tumors, at a late-breaking oral presentation at the upcoming American Association for Cancer Research (AACR) 102nd Annual Meeting 2011 in Orlando, Florida.

PVS-30200, which utilizes Pervasis' proprietary implantable material comprised of healthy allogeneic (donor) endothelial cells embedded in a polymer matrix, is designed to be administered locally to regulate processes involved in tumor growth and metastasis, including cell-proliferation, inflammation and invasion, in order to prevent the spread of cancer to secondary sites in the body. The well-studied patented technology on which PVS-30200 is founded has a proven safety profile as demonstrated by data from six clinical studies in the area of vascular repair.

Joseph Franses, from the Massachusetts Institute of Technology's (MIT) Division of Health Sciences and Technology, is the lead author of the abstract titled, "A first-in-class novel therapy (PVS-30200) for the treatment and prevention of metastatic cancer by regulating the tumor microenvironment," and will present the data at a Late-Breaking Research Session on Cancer Therapeutics and Epidemiology beginning at 3:00 p.m. on Tuesday, April 5, 2011 in Room W415 B/C (Vallencia Ballroom) at the Orange County Convention Center.

"We look forward to presenting PVS-30200 data at AACR and to having an opportunity to communicate the potential for this therapy to the oncology community," said Helen Marie Nugent, PhD, Co-Founder and Vice President, Research and Development at Pervasis and a co-author of the AACR abstract. "We are moving forward aggressively with our development program for PVS-30200 in order to deliver a safer, more effective treatment for solid tumors, preventing cancer recurrence and improvi
'/>"/>

SOURCE Pervasis Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R)
2. Pervasis Therapeutics Awarded Four Grants Under the Qualifying Therapeutic Discovery Project
3. Pervasis Therapeutics to Develop Novel Cell-Based Approach to Target Tumor Environment, Prevent Cancer Recurrence
4. Pervasis to Present Interim Data from Phase 1/2 Clinical Study of Novel Cell Therapy Targeting Peripheral Artery Disease at International Conference on Cell Therapy for Cardiovascular Diseases
5. Pervasis Receives FDA Fast Track Status for Vascugel® to Prevent Arteriovenous Access Failure in Patients Undergoing Hemodialysis
6. Pervasis Receives Orphan Drug Designation in Europe for Vascugel® to Prevent Arteriovenous Access Failure in Patients Undergoing Hemodialysis
7. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
8. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
11. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2015)... Hospira, Inc. (NYSE: ... Biosimilar-Behandlungen, sprach heute auf der jährlichen Konferenz der ... London über die Bedeutung ... Biosimilars für Patienten. Das Unternehmen kündigte ... dem Titel „Why extrapolation is paramount to ...
(Date:4/25/2015)... 2015  With the introduction of Elekta,s new Leksell ... are now available for more patients with a wider ... stereotactic radiosurgery system for the brain, integrates advanced motion ... versatility of Gamma Knife radiosurgery. Elekta unveiled Leksell Gamma ... Forum in Barcelona . ...
(Date:4/24/2015)... Hampshire , und BARCELONA ... -- (Stand Nr. 4410) iCAD, Inc. (Nasdaq: ... von moderner Bildanalyse, Lösungen für Behandlungsabläufe und ... Krebserkrankungen, hat heute die sofortige Verfügbarkeit des ... Electronic Brachytherapy (eBx ® ) System ® ...
Breaking Medicine Technology:Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 2Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 3Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 4Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 5Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 6Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 7Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 8New Leksell Gamma Knife to benefit more patients with brain disease 2New Leksell Gamma Knife to benefit more patients with brain disease 3Erste Klinik in Spanien setzt das Xoft Electronic Brachytherapy System für die Behandlung von Brustkrebs im Frühstadium, nicht-melanozytärem Hautkrebs und gynäkologischen Krebserkrankungen ein 2Erste Klinik in Spanien setzt das Xoft Electronic Brachytherapy System für die Behandlung von Brustkrebs im Frühstadium, nicht-melanozytärem Hautkrebs und gynäkologischen Krebserkrankungen ein 3Erste Klinik in Spanien setzt das Xoft Electronic Brachytherapy System für die Behandlung von Brustkrebs im Frühstadium, nicht-melanozytärem Hautkrebs und gynäkologischen Krebserkrankungen ein 4Erste Klinik in Spanien setzt das Xoft Electronic Brachytherapy System für die Behandlung von Brustkrebs im Frühstadium, nicht-melanozytärem Hautkrebs und gynäkologischen Krebserkrankungen ein 5Erste Klinik in Spanien setzt das Xoft Electronic Brachytherapy System für die Behandlung von Brustkrebs im Frühstadium, nicht-melanozytärem Hautkrebs und gynäkologischen Krebserkrankungen ein 6
... CITY, Calif., Jan. 6, 2012  myoscience, Inc. of Redwood ... Robert E. Grant as Chairman of the Board of ... Chief Executive Officer and President of Bausch & Lomb ... Allergan.  Mr. Grant has been a board member for ...
... USHIFU, LLC (US HIFU), a world leader in minimally ... Klein as the company,s new chief executive officer and ... more than 30 years of experience in oncology and ... as president of the radiation oncology division of Roper ...
Cached Medicine Technology:myoscience Announces Robert Grant as Chairman of the Board 2US HIFU Names New Chief Executive Officer 2US HIFU Names New Chief Executive Officer 3
(Date:4/25/2015)... Washington, DC (PRWEB) April 26, 2015 ... for Seniors (ACE.S) , a national endeavor to prepare ... older adults, is a great success, according to a ... of the program's original funding partners. , The ... College of Philadelphia (CCP), under the direction of Elaine ...
(Date:4/25/2015)... 2015 Diversified Communications has announced ... event. The Integrative Healthcare Symposium Canada, as it’s ... at the Sheraton Parkway Toronto North in Ontario. ... of the most anticipated events of the year ... program. The event aims to gather multi-disciplined practitioners ...
(Date:4/25/2015)... 26, 2015 Avid Collector Andrew Hawley ... Rolling Stones Greensboro Coliseum concert posters. The concert was ... the Stone's Second American Tour. , According to ... out of Baltimore, Maryland. This poster blank was used ... southern cites. Globe uses garish lettering and colors on ...
(Date:4/25/2015)... D.C. (PRWEB) April 25, 2015 In ... worldwide will join The Million Nets Pledge, a two-year ... campaign to protect refugee families with one million bednets ... their increased work with UN partners to protect children, ... from malaria. , “There has been a large ...
(Date:4/25/2015)... The Hon. Ellen Tauscher, Independent Chair of the ... following the deadly earthquake in Nepal: , "Today a ... deaths of more than 1,000 people. The aftershocks ... India and other parts of South Asia. I ... of Nepal and the families of the victims. ...
Breaking Medicine News(10 mins):Health News:Hartford Foundation Report Details Success of NLN's Advancing Care Excellence for Seniors (ACE.S) Program 2Health News:Hartford Foundation Report Details Success of NLN's Advancing Care Excellence for Seniors (ACE.S) Program 3Health News:Integrative Healthcare Event launching in Canada 2Health News:Supporters Worldwide Join The Million Nets Pledge on World Malaria Day 2Health News:Supporters Worldwide Join The Million Nets Pledge on World Malaria Day 3Health News:Supporters Worldwide Join The Million Nets Pledge on World Malaria Day 4
... be as effective as a second medication for as ... not been cured by a single antidepressant medication. ... recently published in the Journal of Clinical Psychiatry, found ... can work as well as administering a second antidepressant ...
... , TUESDAY, Aug. 23 (HealthDay News) -- Accidental ... cancer nurses in the United States, a new study ... state who work in outpatient chemotherapy infusion centers and ... eyes had been exposed to the drugs. In ...
... -- Researchers say boys are becoming physically mature earlier ... reaching sexual maturity about 2.5 months earlier every decade ... reason for earlier maturity for boys, as with girls, ... more favorable for it," demographer Joshua Goldstein, director of ...
... By Maureen Salamon HealthDay Reporter , TUESDAY, ... research investigating injectable drugs to treat psoriasis -- an ... the medications are not linked to higher heart risks. ... complete information from drug makers impeded their ability to ...
... than 1 million patients in North America, results from ... as bacteria, in people genetically predisposed to the disorder. ... colon, is one such condition. The aberrant immune ... small signaling proteins secreted by various cells, including ...
... TUESDAY, Aug. 23 (HealthDay News) -- A test that detects ... likely to raise the risk of invasive cervical cancer, when ... many women than the Pap test alone, a new study ... the HPV test alone appears to be enough, said study ...
Cached Medicine News:Health News:Exercise can substitute effectively as second 'medication' for people with depression 2Health News:Nurses at Risk for Accidental Exposure to Chemo Drugs: Study 2Health News:Boys Mature Sexually Earlier Than Ever Before: Study 2Health News:Injectable Psoriasis Drugs May Not Hike Heart Risks: Study 2Health News:Injectable Psoriasis Drugs May Not Hike Heart Risks: Study 3Health News:Novel cytokine protects mice from colitis 2Health News:HPV Test Might Be Better Predictor of Cervical Cancer Than Pap Smear 2Health News:HPV Test Might Be Better Predictor of Cervical Cancer Than Pap Smear 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: